Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.78% | 12.36% | 8.61% | -13.76% | 9.47% |
| Gross Profit | -3.78% | -12.36% | -8.61% | 13.76% | -11.04% |
| SG&A Expenses | 42.23% | 28.07% | 16.31% | 21.36% | -1.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.57% | 15.76% | 10.08% | -7.56% | 7.06% |
| Operating Income | -11.57% | -15.76% | -10.08% | 7.56% | -8.25% |
| Income Before Tax | -18.39% | -25.34% | -30.62% | 3.98% | -7.89% |
| Income Tax Expenses | -- | -- | -- | 126.67% | -- |
| Earnings from Continuing Operations | -18.39% | -25.34% | -30.62% | 3.95% | -7.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.39% | -25.34% | -30.62% | 3.95% | -7.89% |
| EBIT | -11.57% | -15.76% | -10.08% | 7.56% | -8.25% |
| EBITDA | -10.46% | -14.27% | -9.44% | 6.31% | -8.37% |
| EPS Basic | -16.35% | -23.43% | -13.97% | 21.93% | 12.36% |
| Normalized Basic EPS | -16.34% | -23.43% | 5.86% | 29.63% | 12.35% |
| EPS Diluted | -16.35% | -23.43% | -13.97% | 21.93% | 12.36% |
| Normalized Diluted EPS | -16.34% | -23.43% | 5.86% | 29.63% | 12.35% |
| Average Basic Shares Outstanding | 1.75% | 1.55% | 14.60% | 23.03% | 23.11% |
| Average Diluted Shares Outstanding | 1.75% | 1.55% | 14.60% | 23.03% | 23.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |